News coverage about PAVmed (NASDAQ:PAVM) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PAVmed earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5795572594255 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several brokerages have commented on PAVM. ValuEngine lowered PAVmed from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Dawson James restated a “buy” rating and set a $10.10 price target on shares of PAVmed in a research note on Tuesday, September 5th.
Shares of PAVmed (NASDAQ:PAVM) opened at 8.58 on Friday. The firm’s 50-day moving average price is $7.33 and its 200 day moving average price is $6.60. The firm’s market capitalization is $114.38 million. PAVmed has a 52 week low of $4.50 and a 52 week high of $14.45.
PAVmed (NASDAQ:PAVM) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts anticipate that PAVmed will post ($0.71) EPS for the current year.
In other news, CFO Dennis M. Mcgrath acquired 6,000 shares of PAVmed stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average price of $4.21 per share, with a total value of $25,260.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have purchased 15,835 shares of company stock valued at $63,816. Insiders own 79.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/15/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-pavmed-pavm-stock-price.html.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.